PITTSBURGH, Oct. 20 /PRNewswire/ -- CardiacAssist, Inc. will feature its recently FDA-approved TandemHeart(R) Escort(R) Controller in booth # 345 at the Transcatheter Cardiovascular Therapeutics Conference (TCT) in Washington, D.C., October 23-25, 2006.
The new, lightweight, space-saving Escort Controller is one of three primary components that make up the TandemHeart(R) PTVA(R) percutaneous circulatory support system from CardiacAssist. The TandemHeart System provides up to five liters per minute (lpm) of circulatory support through a cardiac catheterization procedure in as little as 30 minutes. It is FDA approved for extracorporeal circulatory support for up to six hours for procedures not requiring full cardiopulmonary bypass.
At TCT 2006, The TandemHeart System is the subject of a case presentation by Dr. Alan Heldman of Johns Hopkins Hospital entitled, “CardiacAssist TandemHeart Device: Device Description, Indications, and Clinical Studies” on Tuesday, October 24, at 8:15 a.m. The TandemHeart System is also the subject of a poster presentation, “The Role of Percutaneous Ventricular Assist Device (TandemHeart) in High-Risk Coronary Artery Intervention” by Dr. Annapoorna Kini, et. al., Mt. Sinai Medical Center.
The TandemHeart System is featured in a live case transmission from Columbia/New York-Presbyterian Hospital on Monday afternoon. Additionally, the TandemHeart System is in use at the Hospitals of the University of Pennsylvania, Baptist Hospital of Miami, and UC Davis Medical Center, which will be transmitting live cases during TCT as well.
To date, more than 730 worldwide procedures using the TandemHeart System have been completed, and more than 90 hospitals worldwide now use the TandemHeart System for extracorporeal circulatory support.
The TandemHeart System is used in 17 of the top 20 heart and heart surgery hospitals in the U.S. and 11 of the nation’s top 14 hospitals overall. The device has received FDA 510(k) clearance for short-term use and is the only FDA approved device of its kind in the U.S. It is fully reimbursed by Medicare under existing DRG codes.
About CardiacAssist
Founded in 1996, CardiacAssist, Inc. is a privately held, Pittsburgh-based medical device company that develops, manufactures and markets innovative products designed to provide cardiologists and cardiac surgeons with minimally invasive solutions for providing extracorporeal circulatory support. Its vision is to help advance the treatment of heart disease by bridging gaps in current treatment methodologies.
This press release may contain certain forward-looking statements that relate to CardiacAssist’s future business and financial performance. Such statements are subject to a number of risks and uncertainties that may cause the actual events or future results to differ from those discussed herein.
About TCT 2006
The Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics (TCT) meeting is the world’s premier gathering where the latest trends, research findings and techniques in interventional vascular medicine are disseminated to practicing physicians from around the world. In 2006, TCT takes place October 22-27 in Washington, DC.
Media Contact: Dan Snyders Armada Medical Marketing 303-623-1190 x230 dan@armadamedical.com Monica Bush CardiacAssist, Inc. 412-963-7770 x247 mbush@cardiacassist.com
CardiacAssist, Inc.
CONTACT: Dan Snyders of Armada Medical Marketing, +1-303-623-1190 x230,dan@armadamedical.com; or Monica Bush of CardiacAssist, Inc.,+1-412-963-7770 x247, mbush@cardiacassist.com
Web site: http://www.cardiacassist.com/
